FDA Fast-Tracks New ALS Treatment for Genetic Cases
A newly approved ALS treatment can now target specific genetic causes of the disease, offering hope to patients with Lou Gehrig's disease. The FDA fast-tracked the therapy, marking a significant breakthrough in personalized medicine for neurological conditions.
